Verve Therapeutics | 4:持股变动声明-高管 Ashe Andrew D.
Verve Therapeutics | 4:持股变动声明-高管 Nickerson Joan
Verve Therapeutics | 4:持股变动声明-高管 Ashe Andrew D.
Verve Therapeutics | 4:持股变动声明-高管 Kathiresan Sekar
Verve Therapeutics | 4:持股变动声明-高管 Nickerson Joan
Verve Therapeutics | 4:持股变动声明-高管 Fiedorek Fred T.
Verve Therapeutics | 4:持股变动声明-高管 Dorval Allison
Verve Therapeutics | 4:持股变动声明-高管 Bellinger Andrew
Verve Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-The Vanguard Group(6.81%)
Verve Therapeutics | 5:权益变更年度报表-董事 ADELMAN BURT A
Verve Therapeutics | SC 13G:超过5%持股股东披露文件-BlackRock, Inc.(5.6%)
Verve Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-ARK Investment Management LLC(8.74%)
Verve Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-STATE STREET CORPORATION(4.81%)
Verve Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-XXVI Holdings Inc.(15.4%),Alphabet Inc.(15.4%)等
Verve Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-FMR LLC(4.842%),Abigail P. Johnson(4.842%)
Verve Therapeutics | 3:首次持股声明-其他相关方 GV 2023 GP, L.L.C.
Verve Therapeutics | 4:持股变动声明-董事 Yeshwant Krishna
Verve Therapeutics | 4:持股变动声明-首席财务官 Dorval Allison
Verve Therapeutics | 4:持股变动声明-高管 Fiedorek Fred T.
Verve Therapeutics | 3:首次持股声明-高管 Fiedorek Fred T.
暂无数据